The concept of time toxicity: A patient's perspective
The concept of time toxicity: A patient's perspective
ESMO 2022: Breast and ovarian trial analysis
ESMO 2022: Highlights, commentary and analysis
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
ESMO 2022: Renal roundup
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
A new era of early cancer detection with blood test may change cancer screening paradigms